200 million more doses

Biden administration to buy 200 million more doses of Covid vaccine

The administration will ship out at least 10 million doses a week under the new strategy.

By ADAM CANCRYN and RACHEL ROUBEIN

The Biden administration is planning to purchase an additional 200 million doses of Covid-19 vaccine, marking a stepped-up effort to vaccinate the vast majority of Americans this year.

Federal officials negotiating for the new supply expect to receive 100 million doses each from Moderna and Pfizer, in deals set to boost the nation’s total vaccine capacity to 600 million.

That would give the U.S. the ability to eventually vaccinate up to 300 million Americans, President Joe Biden said on Tuesday.

"This is an aggregate plan that doesn’t leave anything on the table or anything to chance," he said. "This is a wartime effort."

Yet the companies will not deliver on those new shots until sometime this summer, raising the possibility of supply shortages that could stretch on for the next several months.

The White House in the interim is boosting the amount of existing vaccine that it sends to states and other jurisdictions each week, as it tries to temper intensifying complaints about scarce supplies across the nation.

The administration will ship at least 10 million doses a week under the new strategy, a roughly 16 percent increase that will be spread across all 50 states and a handful of territories.

The additional supply will last for at least three weeks, senior administration officials said.

“It is a critical step to get much-needed vaccine on the ground and get millions of Americans vaccinated soon,” a senior administration official said.

On a private call Tuesday, Biden officials told governors that next week's distribution would consist of 5.7 million Moderna doses and 4.3 million Pfizer doses, one person with knowledge of the discussion said. That Pfizer total will not count an extra overfill dose that is often found in the vials, according to three people with knowledge. Biden officials also said they plan to send out the special syringes needed to extract those extra doses as part of next week's delivery, one person said.

But the country likely doesn't have enough syringes capable of squeezing out the extra dose, meaning the U.S. may not actually be able to vaccinate 100 million people with Pfizer's allotment.

The Biden administration is also committing to giving states estimates of how much vaccine they will receive at least three weeks in advance. The move comes after states complained they need more advance notice to plan for everything from mass vaccination sites to smaller clinics.

The ramp up in allocations comes as the Biden administration's Covid response team has struggled to get a handle on how much vaccine is available nationwide, as well as account for discrepancies between states and the federal government over how many doses are sitting idle.

More than 41 million shots have been distributed so far, nearly half of which have yet to be administered, according to Centers for Disease Control data.

Yet several states complained in recent weeks that they are running dangerously low on supply, with some going as far as to redirect unused doses from nursing homes to providers serving other priority groups.

“There’s a reporting lag, and they don’t know where the vaccine is,” said Georges Benjamin, executive director of the American Public Health Association, adding that the confusion has contributed to a “hoarding mentality” in the areas where doses are available.

A senior Biden administration official on Tuesday insisted the government is keeping only minimal amounts of vaccine in reserve, and that the vast majority of the unused doses have already been distributed.

The administration is hoping that adding an additional 200 million doses will alleviate those supply issues over the long term, though it remains unclear when agreements with the manufacturers will be finalized and how much the U.S. will have to pay for the extra supply.

The federal government already holds pre-existing options to purchase more vaccine from both Moderna and Pfizer.

Biden earlier this week predicted that anyone who wants a vaccine will be able to get one by the spring, even as some of his top aides have warned it could take well into the late summer or fall before the U.S. is close to reaching the herd immunity needed to effectively end the pandemic.

On Tuesday, Biden appeared to dial back his optimism, acknowledging the supply constraints the nation will face through the first half of the year.

"This is enough vaccine to fully vaccinate 300 million Americans by the end of the summer, beginning of the fall," he said, adding that the first deliveries are expected early in the summer.

Many states have dramatically expanded groups eligible for the shots in order to speed up immunizations. Public health experts have expressed concern about the likelihood that minority communities will have far lower vaccination rates.

The CDC may come out with demographic data on vaccinations as soon as next week, according to a source in communication with the agency.

Moderna and Pfizer have pledged a total of 200 million doses of their Covid shots by the end of March, with another 200 million available over the three months after that.

The U.S. has the option of purchasing another 400 million Pfizer shots and potentially 300 million Moderna shots. But Pfizer is now counting overfill in each of its vaccine vials as an extra full dose toward its vaccine commitment to the U.S. pandemic response — even though not all the syringes the federal government supplies can eke out the extra dose.

The White House is betting heavily on the eventual arrival of a third vaccine from Johnson & Johnson that requires only a single shot compared with the two-dose regimen for Moderna and Pfizer. The federal government has pre-purchased 100 million doses of the company’s shots, and on Tuesday, J&J said it can deliver those doses by the end of June. The U.S. also has an option to buy 300 million more doses.

Johnson & Johnson is expected to report trial data on its vaccine as soon as next week, but earlier this month warned officials it had fallen behind its production schedule and likely would not catch up until the end of April.